Risk of COVID-19 death in adults who received booster COVID-19 vaccinations: national retrospective cohort study on 14.6 million people

in England

Isobel Ward PhD^{1*}, Chris Robertson PhD^{2,3}, Utkarsh Agrawal PhD⁴, Lynsey Patterson PhD^{5,6}, Declan T. Bradley PhD^{5,6}, Ting Shi PhD⁷, Simon de Lusignan MD⁴, FD Richard Hobbs FMedSci⁴, Aziz Sheikh MD⁷, Vahé Nafilyan PhD¹

- 1. Office for National Statistics, Newport, UK
- 2. Department of Mathematics and Statistics, Strathclyde University, Glasgow, Scotland
- 3. Public Health Scotland, Glasgow, Scotland
- 4. Nuffield Department of Primary Care Health Sciences, University of Oxford, UK
- 5. Centre for Public Health, Queen's University Belfast, Belfast, UK
- 6. Public Health Agency, Belfast, UK
- 7. Usher Institute, University of Edinburgh, Edinburgh, UK

*Corresponding author: lsobel.Ward@ons.gov.uk

Word count: 2834

Key Points

Question: What health conditions are associated with increased risk of postbooster COVID-19 death in adults who received a COVID-19 vaccination in autumn 2022?

Findings: Certain groups were found to be at overall higher risk of postbooster COVID-19 death (e.g., learning disability or Down Syndrome) and certain groups were found to have significantly higher relative risk of COVID-19 death compared to other non-COVID-19 causes (e.g., cancer of the blood or bone marrow).

Meaning: This work has implications for prioritisation of vaccination booster doses worldwide. We highlight which groups with health conditions are at elevated risk of postbooster COVID-19 death.

Abstract

Importance: The emergence of the COVID-19 vaccination has been critical in changing the course of the COVID-19 pandemic, with estimates suggesting vaccinations have prevented millions of deaths worldwide. To ensure protection remains high in vulnerable groups booster vaccinations in the UK have been targeted based on age and clinical vulnerabilities.

Objective: We sought to identify adults who had received a booster vaccination as part of the autumn 2022 campaign in England yet remained at increased risk of postbooster COVID-19 death and compared to non-COVID-19 risk.

Design, Setting, and Participants: We undertook a national retrospective cohort study using data from the 2021 Census linked to electronic health records. We fitted cause-specific Cox models to examine the association between health conditions and the risk of COVID-19 death and all-other-cause death for adults aged 50-100-years in England vaccinated with a booster in autumn 2022. Our total population was 14,644,570 people; there were 6,800 COVID-19 deaths and 150,075 non-COVID-19 deaths.

Exposure: Sociodemographic characteristics (sex, age, ethnic group, region), disability, body mass index, and diagnosis of a health condition defined from QCovid2.

Main Outcomes and Measures: The primary outcome of this study was COVID-19 death. The secondary outcome was all-cause non-COVID-19 deaths.

Results: Having learning disabilities or Down Syndrome (hazard ratio=5.07;95% confidence interval=3.69-6.98), pulmonary hypertension or fibrosis (2.88;2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington's disease (2.94, 1.82-4.74), cancer of blood and bone marrow (3.11;2.72-3.56), Parkinson's disease (2.74;2.34-3.20), lung or oral cancer (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) or liver cirrhosis (2.65;1.95 to 3.59) was associated with an increased risk of COVID-19 death. Individuals with cancer of the blood or bone marrow, chronic kidney disease, cystic fibrosis, pulmonary hypotension or fibrosis, or rheumatoid arthritis or systemic lupus erythematosus had a significantly higher risk of COVID-19 death relative to other causes of death compared with individuals who did not have diagnoses.

Conclusions, and Relevance: We identify groups who are at increased risk of postbooster COVID-19 death relative to non-COVID-19 deaths. Policy makers should continue to priorities vulnerable groups for subsequent COVID-19 booster doses to minimise the risk of COVID-19 death.

Funding: National Core Studies–Immunity, National Core Studies–Data and Connectivity, Health Data Research UK, and the Medical Research Council.

Introduction

The development and rollout of COVID-19 vaccinations has significantly reduced severe COVID-19 infection, morbidity, and mortality [1]. However, some groups of patients remained at elevated risk of COVID-19 death despite having received a primary vaccination course. In addition, the effectiveness has been found to decline over time [2]. As a result, booster doses were needed to ensure that the population remains protected against severe outcomes, especially as restrictions controlling infections have been removed. In the UK, the first booster doses were offered to every adult three months after having a second COVID-19 vaccine dose [3]. Subsequent booster doses were then offered to groups at increased risk of hospitalisation or death, such as older adults, people with some health conditions, or individuals who were in contact with vulnerable patients, such as healthcare workers [4].

Continuing to protect the most vulnerable people against COVID-19 remains critical to minimise the direct and indirect impact of SARS-CoV-2 on population health and health services, especially as most countries transition to long-term management of the COVID-19 pandemic [5]. Identifying patients at greatest risk of severe outcomes from SARS-CoV-2 infection is important to ensure that the booster doses are offered to those who need them whilst managing the cost of the vaccination programme. Existing evidence suggests that besides age, having comorbidities and specific conditions such as chronic kidney disease (CKD) is associated with an increased risk of COVID-19 hospitalisation and death in individuals who had received a full vaccination schedule and a first booster dose [6]. However, there is little evidence on the risk factors for COVID-19 death for individuals who have received a second booster vaccination in autumn 2022 in England. Understanding the risk for different groups of individuals is imperative to inform the Joint Committee on Vaccination and Immunisation (JCVI) in the UK and equivalent international bodies decision making on prioritisation of subsequent booster vaccinations.

In this study, we aimed to identify the groups of adults who were at elevated risk of COVID-19 death, among those who had received a second booster dose of a COVID-19 vaccine as part of England's 2022 autumn booster campaign. Using a linked dataset based on the 2021 Census [7] linked to primary care records and death registration data, we estimated the hazard ratio of death involving COVID-19 for a range of sociodemographic characteristics (sex, age, ethnic group, and measures of socioeconomic position) and clinical risk factors. We also estimated the hazard ratio of death not involving COVID-19, to understand which groups were at higher risk of COVID-19 death but had otherwise a relatively low risk of death.

Methods

Data sources

We used person-level data comprising individuals in the 2021 Census, linked to the Personal Demographics Service (PDS) [8], to obtain NHS numbers with a linkage rate of 94.6%. These individuals were then linked via NHS number to Office for National Statistics(ONS) death registrations [9] (including deaths registered up to April 26, 2023) and other electronic health records. Vaccination records were obtained from the National Immunisation Management Service (NIMS) [10] Health related variables from primary care records were derived from the General Practice Extraction Service (GPES) data for Pandemic Planning and Research version 4 (GDPPR) and linked via NHS number. The linked dataset included data on 52 million people residents in England, which covers (accounting for linkage and non-respondents) approximately 91.8% of the population of England on Census day in 2021.

Study population

This study was a retrospective cohort study that included individuals vaccinated with a COVID-19 booster dose in England after September 1, 2022, were enumerated in Census 2021, linked to the PDS, and were aged 50-100-years of age on the date of booster administration. An autumn booster dose was defined as a booster dose administered on or after September 1, 2022, and at least 84 days since the last clinically acceptable dose, and individuals must have had at least two doses prior to the booster (Supplementary Figure 1). See supplementary Table 1 for sample flow.

Outcome

The primary outcome of this study was COVID-19 death, defined as any International Classification of Diseases (ICD) death with codes U07.1 and U07.2 [11] recorded anywhere on the death certificate, which occurred up to April 11, 2023, and were registered by April 26, 2023 (allowing for 15 days for death registration). The secondary outcome was all-cause non-COVID-19 deaths.

Individuals were followed from 14-days after the autumn dose booster vaccination date until April 11, 2023. Time at risk started 14 days after booster vaccination and ended at time of death (either COVID-19 or other), or end of study (April 11, 2023).

Exposures

The predictors included in the model included sociodemographic characteristics from Census 2021 and clinical risk factors from primary care data. The medical conditions were derived using primary care records from General Practice Extraction Service (GPES) data for Pandemic Planning and Research version 4 (GDPPR) based on the definitions used by the QCovid2 [12], [13] risk prediction model, using data between March 1, 2015, and March 21, 2021 (Census day). The QCovid risk prediction model was used by the NHS in Great Britain to identify individuals who are particularly vulnerable to COVID-19 hospitalisation and death. The model has been validated previously using the PHDA [14] and data from Scotland [15]. All predictors included in the model are summarised in Table 1. Missing items for Census characteristics were imputed using nearest-neighbour donor imputation,

the methodology employed by ONS across all 2011 Census variables. Missing Body Mass Index (BMI) information was handled by including a 'Missing category.

Statistical analysis

We used cause-specific Cox regression to examine the association between each of the health comorbidities and the risk of COVID-19 death and all-other-cause mortality. Time at risk started 14 days after receipt of the autumn booster dose and ended either at time of death or end of study period (April 11, 2023). For each outcome (COVID-19 and non-COVID-19), we first fitted a model adjusted for age (restricted cubic spline with boundary knots at the 5th and 95th percentile with 3 internal knots), sex and calendar time (restricted cubic spline with boundary knots at the 5th and 95th percentile with 3 internal knots) (Model 1), next added ethnic group and region (Model 2), BMI (Model 3) and disability (Model 4).

For each of the health comorbidities we fitted a model adjusted for all QCovid health conditions, age (spline), sex, calendar time (spline), ethnic group and region (Model 5). In addition, we fitted separate models for each health conditions, adjusted for age (restricted cubic spline), sex, calendar time (restricted cubic spline), ethnic group and region. For computational reasons, the analysis was performed on a dataset containing every individual who died and a weighted 5% sample of those who survived up until the end of study. To test for differences in risk between COVID-19 and non-COVID-19 models for people who had diagnoses of health comorbidities, Z-statistics were calculated for each coefficient from models (Model 5) with bootstrapped data (1000 iterations). The bootstrapping was run on the sampled data ensuring the proportion of outcomes (death and alive) was preserved. Analysis was conducted using Spark version 2.4.0 and R version 3.5.1. All counts have been rounded to the nearest 5, with values less than 10 suppressed for disclosure reasons.

Ethical approval

This study was approved by the National Statisticians Ethics Board and was conducted in accordance with the Declaration of Helsinki. As this study used anonymised electronic health records, informed consent was not required.

Results

There were 14,651,440 adults aged 50-100 years in our study population (mean = 67.9 years, standard deviation (SD) = 10.9); 46.9% were male and 90.4% were White British. Descriptive characteristics of the study population are reported in Table 1. Between September 1, 2022, and April 11, 2023, there were 6,800 COVID-19 deaths (52.2% male), and 150,075 non-COVID-19 deaths, 1 (48.4% male). The mean age of those who died from COVID-19 was 84.0 years (SD) = 8.87) and for non-COVID-19 deaths was 82.3 years (SD = 9.85).

Age was an important predictor of both COVID-19 and non-COVID-19 death; risk was xx times greater for an 80-year-old relative to a 50-old for COVID-19 related death (HR:46.4;95%CI:43.0-50.0), and xx times greater for non-COVID-19 related death (HR:29.6; 95%CI:29.2-30.0) (Figure 1, Table 2). Women were at a lower risk of COVID-19 death (HR:0.63; 95%CI 0.6-0.66) and non-COVID-19 death (HR:0.76; 95%CI:0.75-0.77) relative to men (Model 1) (Table 2). We found a significantly lower risk of COVID-19 deaths for Black Caribbean (HR:0.46; 95%CI:0.29-0.73), Indian (HR:0.75;95%CI:0.58-0.95) and the other ethnic group (HR:0.62;95%CI:0.45-0.87) relative to the White British group for COVID-19 outcomes (Model 2) (Table 2). Being morbidly obese or underweight is associated with an increased risk of COVID-19 (Morbidly obese = HR:1.60;95%CI:1.35-1.89, Underweight = HR:2.29;95%CI:2.04-2.59) and non-COVID-19 death (Morbidly obese = HR:1.55;95%CI:1.50-1.60, Underweight = HR:2.45;95%CI:2.39-2.51) (Model 3) (Table 2). Self-reporting a disability which reduced an individual's day-to-day activities a little or a lot was associated with higher risk or COVID-19 and non-COVID-19 deaths relative to non-disabled people (Model 4) (Table 2).

Overall, the conditions with the highest risk of COVID-death relative to not having the condition (HR > 2) were people with learning disabilities or Down's syndrome (HR:5.07;95%CI:3.69-6.98), those with pulmonary hypertension or fibrosis (HR:2.88;95%CI:2.43-3.40), motor neuron disease, multiple sclerosis, myasthenia or Huntington's disease (HR:2.94;95%CI:1.82-4.74), cancer of blood and bone marrow (HR:3.11;95%CI:2.72-3.56), Parkinson's disease (HR:2.74;95%CI:2.34-3.20), lung or oral cancer (HR:2.57:95%CI:2.04-3.24), dementia (HR:2.64;95%CI:2.46-2.83), or liver cirrhosis (HR:2.65;95%CI:1.95-3.59) (Figure 2, Table 2).

Comparing the HRs of COVID-19 and non-COVID-19 deaths, we found a higher relative risk of COVID-19 death compared to non-COVID-19 death for the following conditions: cancer of blood or bone marrow, CKD, cystic fibrosis, pulmonary hypotension or fibrosis or rheumatoid arthritis or systemic lupus erythematosus (SLE) (Supplementary table 2). Conversely, we found relative risk of dying from non-COVID-19 causes was higher than COVID-19 deaths for dementia and liver cirrhosis relative to those who do not have these conditions.

In the supplementary model not adjusted for other health comorbidities, the risk of COVID-19 outcomes was elevated relative to the model where the other conditions were adjusted for (Supplementary Table 3). Interestingly, for asthma in the model adjusted for other health conditions (Model 5) the HR for COVID-19 outcomes was lower than 1 (HR:0.84;95%CI:0.77-0.95), however in the supplementary model (adjusted for sex, age, region, ethnic group, and calendar time) the risk was

significantly higher for people diagnosed with asthma compared to without (HR:1.22;95%CI:1.11-

1.33) (Supplementary Table 3).

Discussion

This national investigation has identified adults who remained at increased risk of COVID-19 death after receiving a second dose booster vaccination in England in Autumn 2022. Our results indicate that having learning disabilities or Down's syndrome, pulmonary hypertension or fibrosis, motor neuron disease, multiple sclerosis, myasthenia or Huntington's disease, cancer of blood and bone marrow, Parkinson's disease, lung or oral cancer, dementia or liver cirrhosis were independently associated with a higher risk of COVID-19 related death. For cancer of blood or bone marrow, CKD, cystic fibrosis, pulmonary hypotension or fibrosis or rheumatoid arthritis or SLE the increase in the relative risk was greater for COVID-19 death than non-COVID-19 death. Our findings suggest individuals in those groups were particularly vulnerable to COVID-19 death relative to other causes of death. For instance, for people with rheumatoid arthritis or SLE, the risk of dying from non-COVID-19 causes was not significantly different from people without these diagnoses; however, the risk was higher for COVID-19 death. Importantly, this group was not identified as one of the listed health comorbidities with the highest overall risk of COVID-19 death, but our analysis highlights the importance of relative risk with individuals being more likely to die from COVID-19 in this group relative to other causes.

For many health conditions the increase in risk of COVID-19 death was similar to, or lower than, the increase in risk of non-COVID-19 deaths, suggesting that the increase in the risk of COVID-19 death was not different to the increase in the risk of death from other causes. Whilst we find that patients with asthma were at elevated risk of COVID-19 death after accounting for age, sex, ethnic group and region, we found that having asthma was not associated with the risk of COVID-19 death after adjusting for other comorbidities, suggesting that asthma was not directly increasing the risk of COVID-19 death.

Our findings support previous research which has assessed mortality outcomes following first dose COVID-19 booster vaccinations [16]. Overall, in the UK first dose booster vaccinations have been found to reduce severe outcomes (hospitalisation and death), with particular groups remaining at elevated risk [2].Older adults (over 80 years of age), those with health comorbidities and specific conditions such as CKD were found to be at elevated risk. A study conducted in the United States reported that in patients who were immunocompromised, diabetic, had CKD or chronic lung disease there was a graded increase in risk of breakthrough COVID-19 infections positively associated with the number of comorbidities following two primary doses [17]. It is important to consider the results presented in our study may not reflect the differences in risk of COVID-19 death following infection. Our study looks at the risk of death since the time of having received a second booster dose, not since infection. It is possible that the risk of infection also differs by clinical risk factors, as patients who are the most vulnerable may maintain social isolation to protect themselves. It is also possible that some vulnerable patients may be at greater risk of infection because they live in communal establishments or have frequent contacts with carers or medical staff.

Critically, our work is the first to assess the impact of the autumn 2022 booster vaccination on COVID-19, but additionally non-COVID-19 outcomes in adults in England. Our results provide strong evidence to inform JCVI about which groups should be prioritised for the autumn 2023 and possibly subsequent boosters. It is critical to highlight the fact that some groups who do not have the overall highest risk of COVID-19 death, have an increased risk relative to non-COVID-19 causes and thus should remain a key priority.

Our study has several strengths. Firstly, we used population level data for England based on a unique linkage of the 2021 Census to electronic health records. Sociodemographic characteristics, including ethnic group, were derived from the 2021 Census, and were accurate and had low missingness, unlike in some electronic health records, where ethnic group is often missing and not always self-reported [18]. Second, we identified the clinical risk factors using primary care data. Third, we used information on the cause of death to define COVID-19 death and were also able to examine non-COVID-19 death as a comparator and identify which conditions were associated with a relative increased risk of larger for COVID-19 death than for non-COVID-19 death.

An important limitation of our study is the use of 2021 Census for our population means that people who did not respond to the Census were excluded. In addition, it also excluded Census respondents who could not be linked to the Personal Demographics Service (PDS). However, the data we used covered 96.0% of those who received a booster dose in England the autumn of 2022. One of the limitations of our work was the lack of data on COVID-19 hospital admissions [19]. In order to effectively manage resource and understand which groups are at the highest risk of hospitalisation, subsequent work with access to timely data should account for hospital admittance. Additionally, we are unable to account for behaviours which would be classified as health protective such as minimising social contact in the present study. Therefore, it is important to consider for some patients whose risk of hospitalisation or death was most pertinent following SARS-CoV-2 infection, they may be maintaining social isolation to protect themselves. Hence for groups of individuals where the risk was not higher for COVID-19 outcomes, but overall was greater for all-cause death we must maintain prioritisation of vaccination to these individuals. Subsequent research should explore common conditions (e.g., asthma) to understand if the interaction between having a common diagnosis in addition to another specific condition results in a particular susceptibility to adverse COVID-19 outcomes.

Conclusions

Our work is the first to investigate the risk of cause-specific COVID-19 death, as well as non-COVID-19 death in a cohort of adults who received a booster dose in the autumn of 2022. In order to effectively manage the COVID-19 risk, it is imperative that the most vulnerable groups of individuals are prioritised for COVID-19 booster vaccinations. We highlight that the risk of COVID-19 death, compared to all other cause death, remains particularly high in adults with learning disabilities or Down syndrome, pulmonary hypertension or fibrosis, motor neuron disease, multiple sclerosis, myasthenia or Huntington's disease, cancer of blood and bone marrow, Parkinson's disease, lung or oral cancer, dementia, or liver cirrhosis. These groups of patients should be a key priority for subsequent vaccinations, therapeutics and novel treatment. In addition, we highlight the risk associated with a range of health conditions and sociodemographic characteristics which should inform policy makers and researchers with key demographics of interest for subsequent research and vaccination.

References

- S. Kerr *et al.*, "Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales," no. October 2022, pp. 22–31, 2023, doi: https://doi.org/10.1093/ije/dyac199.
- [2] U. Agrawal *et al.*, "Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales," *Lancet*, vol. 400, no. 10360, pp. 1305– 1320, 2022, doi: 10.1016/S0140-6736(22)01656-7.
- [3] E. Rough, "Coronavirus]: Covid-19 booster vaccines frequently asked questions," 2022.
 [Online]. Available: https://commonslibrary.parliament.uk/research-briefings/cbp-9332/#:~:text=In addition%2C the JCVI advised,third primary and booster dose".
- [4] Greenbook Chapter: COVID-19 SARS-CoV-2, no. April. 2023. [Online]. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/ file/1153300/Greenbook-chapter-14a-26April2023.pdf
- [5] World Health Organization, "Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic," 2023. https://www.who.int/news/item/05-05-2023statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergencycommittee-regarding-the-coronavirus-disease-(covid-19)-pandemic
- [6] U. Agrawal *et al.*, "COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study," *Lancet Respir. Med.*, vol. 9, no. 12, pp. 1439–1449, Dec. 2021, doi: 10.1016/S2213-2600(21)00380-5.
- [7] Office for National Statistics, "Census 2021." https://census.gov.uk/
- [8] NHS, "Personal Demographics Service." https://digital.nhs.uk/services/demographics
- "Mortality statistics in England and Wales QMI," Office for National Statistics, 2022.
 https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/met
 hodologies/mortalitystatisticsinenglandandwalesqmi
- [10] N. England, "The National Immunisation Management Service." https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccinationprogramme/#immunisation
- [11] World Health Organization, "ICD-10 Version:2019." https://icd.who.int/browse10/2019/en#/U07.1
- [12] "QCovid® risk calculator." https://www.qcovid.org/

- [13] V. Nafilyan *et al.*, "An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in England," *Lancet Digit. Heal.*, vol. 3, no. 7, pp. e425–e433, 2021, doi: 10.1016/S2589-7500(21)00080-7.
- [14] V. Nafilyan *et al.*, "An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in England," *Lancet Digit. Heal.*, vol. 3, no. 7, 2021, doi: 10.1016/S2589-7500(21)00080-7.
- [15] C. R. Simpson *et al.*, "External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland," *Thorax*, p. thoraxjnl-2021-217580, Nov. 2021, doi: 10.1136/thoraxjnl-2021-217580.
- [16] V. Nafilyan, I. L. Ward, C. Robertson, and A. Sheikh, "Evaluation of Risk Factors for Postbooster Omicron COVID-19 Deaths in England," *JAMA Netw. Open*, vol. 5, no. 9, p. E2233446, 2022, doi: 10.1001/jamanetworkopen.2022.33446.
- [17] P. D. Smits *et al.*, "Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities," *Vaccine*, vol. 41, no. 15, pp. 2447–2455, 2023, doi: 10.1016/j.vaccine.2023.02.038.
- [18] Office for National Statistics, "Understanding consistency of ethnicity data recorded in healthrelated administrative datasets in England: 2011 to 2021," 2023. https://www.ons.gov.uk/releases/understandingconsistencyofethnicitydatarecordedinhealthrela tedadministrativedatasetsinengland2011to2021
- [19] L. Berec *et al.*, "Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia," *PLoS One*, vol. 17, no. 7 July, pp. 1–13, 2022, doi: 10.1371/journal.pone.0270801.

Figures and Tables





Figure 1: Association between age and risk of COVID-19 death

Hazard ratios (HRs) were calculated with a Cox regression model which was adjusted for age, sex and calendar time. The reference HR is for a 50-year-old male.

Figure 2: Risk factors for COVID-19 and non-COVID-19 death in boosted adults



Hazard ratios (HRs) were calculated with a Cox regression model which was adjusted for age, sex, calendar time, ethnicity, region and all other health conditions (Model 5). The dashed lines illustrate an HR of 1. The reference for all conditions is no diagnosis of the specified condition. The COVID-19 outcomes are shown in green and non-COVID-19 outcomes in purple.

Category	Level	Populatio n size	Number of COVID-19 deaths	Number of deaths from all other causes	
Sex	Female	7777290	3250	77415	
Sex	Male	6874150	3550	72660	
Ethnic group	Bangladeshi	26945	С	115	
Ethnic group	Black African	80075	С	190	
Ethnic group	Black Caribbean	75745	20	655	
Ethnic group	Chinese	63825	С	240	
Ethnic group	Indian	271685	65	1615	
Ethnic group	Mixed	91620	20	440	
Ethnic group	Other	231670	35	955	
Ethnic group	Pakistani	61260	25	315	
Ethnic group	White British	13245040	6430	141420	
Ethnic group	White other	503570	185	4135	
Age group	50-59	3937145	100	4030	
Age group	60-69	4343845	365	12630	
Age group	70-79	4045260	1375	35330	
Age group	80-89	2015780	3270	65260	
Age group	90+	309410	1695	32830	
Region	East Midlands	1372080	655	14265	
Region	East of England	1785825	940	17380	
Region	London	1318600	510	10670	
Region	North East	753225	395	8215	
Region	North West	1863550	885	20620	
Region	South East	2704300	1190	26355	
Region	South West	1850480	815	19860	
Region	Wales	9180	С	70	
Region	West Midlands	1502670	755	16325	
Region	Yorkshire and The Humber	1491530	655	16320	
Disability	No	9267175	1855	44370	
Disability	Yes - not reduced at all	1567430	285	7165	
Disability	Yes - reduced a little	2258160	1645	33105	
Disability	Yes - reduced a lot	1558675	3015	65435	
Body Mass Index	Ideal	3167205	2200	46040	
Body Mass Index	Unknown	3648595	1125	27055	
Body Mass Index	Morbidly Obese	429585	150	3705	
Body Mass Index	Obese	3071190	1140	26225	
Body Mass Index	Overweight	4197805	1870	40045	
Body Mass Index	Underweight	137065	310	7005	
Motor neurone disease /Multiple		10075	15	345	

Table 1: Characteristics of the study population, predictor groupings and deaths

sclerosis/Myasthenia/Hunt			
ington's/Chorea			
Prescribed leukotriene	2258625	1705	34950
Liver Cirrhosis	36340	40	1245
Asthma	1002535	470	9485
Prior Fracture ***	14145	30	725
Severe mental illness	1065440	495	11665
Epilepsy	78215	60	1525
Cystic fibrosis *	111300	195	2820
Heart Failure	305260	830	15980
Lung or Oral Cancer	32645	75	1570
Pulmonary Hypertension	33780	145	2070
or Fibrosis			
Peripheral Vascular Disease	123900	205	4585
Dementia	203925	955	23940
Diabetes: Type 2	1458875	1180	26075
Chronic Kidney Disease (CKD)	748840	1335	25065
Diabetes: Type 1	405870	330	7350
Atrial Fibrillation	635745	1175	23655
Schizophrenia	76430	50	1160
Cancer of Blood or Bone Marrow	95450	240	2720
Chronic obstructive pulmonary disease (COPD)	616950	990	19575
Rheumatoid Arthritis or Systemic lupus erythematosus (SLE)	167985	185	2850
Parkinson's Disease	63055	165	3565
Learning Disability or Down Syndrome	54010	40	905
Thrombosis or pulmonary embolus	1810	С	50
Stroke **	372810	610	12960
Immunosuppressed	300360	315	5240
Congenital Heart Problem	20060	10	305
Coronary Heart Disease	688580	820	16005

* - Cystic fibrosis, bronchiectasis or alveolitis, ** - Stroke or transient ischaemic attack (TIA), *** - Prior fracture of hip, wrist, spine or humerus

 Table 2: Sociodemographic characteristics and health conditions associated with COVID-19

 and non-COVID-19 death


Category	Level	Hazard Ratio (HR) for death involving COVID-19	Lower confidence limit for death involving COVID-19	Upper confidence limit for death involving COVID-19	Hazard Ratio (HR) for death not involving COVID-19	Lower confidenc e limit for death not involving COVID-19	Upper confiden ce limit for death not involving COVID- 19
Age	50 years	1.00	0.76	1.31	1.00	0.95	1.05
Age	60 years	2.43	2.31	2.57	2.86	2.83	2.89
Age	70 years	9.32	8.64	10.06	8.57	8.46	8.68
Age	80 years	46.35	43.00	49.96	29.62	29.23	30.01
Age	90 years	210.80	195.52	227.28	118.10	116.51	119.71
Sex	Female	0.63	0.60	0.66	0.76	0.75	0.77
Ethnic group	Banglade shi	0.40	0.10	1.61	1.01	0.84	1.21
Ethnic group	Black African	0.80	0.41	1.53	0.69	0.59	0.79
Ethnic group	Black Caribbea n	0.46	0.29	0.73	0.82	0.76	0.88
Ethnic group	Chinese	0.57	0.29	1.09	0.64	0.57	0.73
Ethnic group	Indian	0.75	0.58	0.95	0.82	0.78	0.86
Ethnic group	Mixed	1.12	0.74	1.70	0.95	0.87	1.04
Ethnic group	Other	0.62	0.45	0.87	0.72	0.68	0.77
Ethnic group	Pakistani	1.19	0.79	1.79	0.73	0.65	0.81
Ethnic group	White other	0.89	0.77	1.03	0.92	0.89	0.95
Body Mass Index	Unknown	0.64	0.59	0.69	0.71	0.70	0.72
Body Mass Index	Morbidly obese	1.60	1.35	1.89	1.55	1.50	1.60
Body Mass Index	Obese	0.87	0.81	0.94	0.90	0.88	0.91
Body Mass Index	Overweig ht	0.76	0.71	0.81	0.77	0.76	0.78
Body Mass Index	Underwei ght	2.29	2.04	2.59	2.45	2.39	2.51
Disability	Yes - not reduced at all	0.99	0.87	1.12	1.03	1.00	1.05
Disability	Yes - reduced a	2.24	2.10	2.40	2.00	1.98	2.03

	little						
Disability	Yes - reduced a lot	4.55	4.29	4.84	4.50	4.44	4.56
Motor neurone disease /Multiple sclerosis/M yasthenia/		2.94	1.82	4.74	2.77	2.49	3.08
Huntington' s/Chorea Prescribed		1.30	1.21	1.40	1.25	1.23	1.27
leukotriene Liver		2.65	1.95	3.59	3.44	3.25	3.64
Cirrhosis Asthma		0.86	0.77	0.95	0.80	0.78	0.82
Prior Fracture ***		1.15	0.80	1.66	1.41	1.31	1.51
Severe mental illness		1.26	1.15	1.39	1.25	1.23	1.28
Epilepsy		1.49	1.15	1.92	1.63	1.55	1.71
Cystic		1.49	1.13	1.92	1.16	1.11	1.71
fibrosis *							
Heart Failure		1.75	1.62	1.90	1.69	1.66	1.72
Lung or Oral Cancer		2.57	2.04	3.24	2.58	2.46	2.72
Pulmonary Hypertensi on or Fibrosis		2.88	2.43	3.40	2.24	2.14	2.34
Peripheral Vascular Disease		1.39	1.21	1.60	1.55	1.51	1.60
Dementia		2.64	2.46	2.83	3.37	3.32	3.42
Diabetes: Type 2		1.20	1.12	1.29	1.24	1.23	1.26
Chronic Kidney Disease (CKD)		1.29	1.21	1.38	1.16	1.14	1.18
Diabetes: Type 1		1.28	1.13	1.44	1.27	1.24	1.31
Atrial Fibrillation		1.26	1.18	1.34	1.27	1.25	1.29
Schizophre nia		1.46	1.08	1.96	1.43	1.34	1.52

Cancer of Blood or Bone Marrow	3.11	2.72	3.56	1.71	1.64	1.78
Chronic obstructive pulmonary disease (C OPD)	1.81	1.66	1.97	1.77	1.74	1.80
Rheumatoi d Arthritis or Systemic lupus erythemato sus (SLE)	1.46	1.24	1.72	1.08	1.04	1.13
Parkinson's Disease	2.74	2.34	3.20	2.65	2.56	2.74
Learning Disability or Down Syndrome	5.07	3.69	6.98	4.08	3.82	4.36
Thrombosis or pulmonary embolus	1.93	0.62	5.99	1.52	1.16	2.00
Stroke **	1.33	1.22	1.44	1.33	1.31	1.36
Immunosup pressed	1.75	1.53	1.99	1.58	1.53	1.63
Congenital Heart Problem	0.92	0.52	1.62	1.17	1.05	1.31
Coronary Heart Disease	1.09	1.01	1.17	1.04	1.02	1.06

Hazard ratios (HRs) were calculated with a Cox regression model which was adjusted for: **age**, **sex**, and calendar time (Model 1), plus **ethnic group** (Model 2), and **BMI** (Model 3), and **disability** (Model 4) and **health conditions** (Model 5).

* - Cystic fibrosis, bronchiectasis or alveolitis, ** - Stroke or transient ischaemic attack (TIA), *** - Prior fracture of hip, wrist, spine or humerus



	1	covid	5.07 (3.69 - 6.98)	-	non-co	4.08 (3.82 - 4.36)
arning Disability or Downs Syndrome		2.05 (4.05	•			
Liver Cirrhosis -		2.65 (1.95 - 3.5				3.44 (3.25 - 3.64)
Dementia -		2.64 (2.46 - 2.83	3)			3.37 (3.32 - 3.42)
MS/Myaesthenia/Huntingtons/Chorea -		2.94 (1.82 -	4.74)			2.77 (2.49 - 3.08)
		2.74 (2.34 - 3.	2)			2.65 (2.56 - 2.74)
Parkinsons Disease -		2.57 (2.04 - 3.24)			2.58 (2.46 - 2.72)
Lung or OralCancer		2.88 (2.43 -	3.4)		2.24	(2.14 - 2.34)
Pulmonary Hypertension or Fibrosis -		3.11 (2.72	2 - 3.56)		1.71 (1.64 - 1.	78)
Cancer of Blood or Bone Marrow -	1.	81 (1.66 - 1.97)			1.77 (1.74 -	1.8)
COPD -		1.93 (0.62 - 5.99)			1.52 (1.16 - 2)	60.50
Thrombosis or pulmonnary embolus		75 (1.62 - 1.9)			1.69 (1.66 - 1.)	72)
Heart Failure -		5 (1.53 - 1.99)			1.58 (1.53 - 1.63)	
immmunosuppressed -	1.49 (1.15	• • • • • • • • • • • • • • • • • • •			1.63 (1.55 - 1.7)	
Epilepsy -	•					0
Peripheral Vascular Disease	1.39 (1.21 -				1.55 (1.51 - 1.6)	
Schizophrenia -	1.46 (1.08	Lange of the second state of the			1.43 (1.34 - 1.52)	
Cystic fibrosis * -	1.59 (1	.37 - 1.84)		1.1	6 (1.11 - 1.2)	
Stroke ** -	1.33 (1.22 - 1	.44)			1.33 (1.31 - 1.36)	
Prescribed leukotriene -	1.3 (1.21 - 1.4	4)			1.25 (1.23 - 1.27)	
	1.15 (0.8 - 1.66)				1.41 (1.31 - 1.51)	
Prior Fracture *** -	1.28 (1.13 - 1.4	4)			1.27 (1.24 - 1.31)	
Diabetes: Type 1 -	1.46 (1.24	- 1.72)		1.08 (1.04 - 1.13)	
Rheumatoid Arthritis or SLE	1.26 (1.18 - 1.3	4)			1.27 (1.25 - 1.29)	
Atrial Fibrillation -	1.26 (1.15 - 1.3				1.25 (1.23 - 1.28)	
Severe mental illness	1.29 (1.21 - 1.3				6 (1.14 - 1.18)	
Chronic Kidney Disease -	1.2 (1.12 - 1.29)				1.24 (1.23 - 1.26)	
Diabetes: Type 2 -						
Coronary Heart Disease	1.09 (1.01 - 1.17)			10 CAR - 50 C	02 - 1.06)	
Congenital Heart Problem -	0.92 (0.52 - 1.62)				7 (1.05 - 1.31)	
Asthma -	0.86 (0.77 - 0.95)			0.8 (0.78 - 0.82)		
		2		ļi		2 4 6